NORMAL SITUATION

MedCap

Financial year 2024 · closed on 31/12/2024
Net result
123,3 k €
+289.1% YoY
Gross margin
176,5 k €
+819.6% YoY
Equity
167,7 k €
+277.8% YoY

Company — Normal situation.

What does MedCap do?

MedCap is a company registered in Belgium.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0776.585.562
Legal form
Private limited company
Contributed capital
162 000,00 €
Latest accounts
31/12/2024
Joint committees (1)
  • 200
Signals
ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 3 financial years

202420232022
Income statement
Gross margin176,5 k €19,2 k €-27,7 k €
EBITDA123,5 k €-56,6 k €-45,4 k €
Operating result123,5 k €-65,2 k €-52,4 k €
Net result123,3 k €-65,2 k €-52,4 k €
Balance sheet
Equity167,7 k €44,4 k €69,6 k €
Total assets207,5 k €80,6 k €84,9 k €
Cash1,8 k €14,6 k €5,1 k €
Debts39,8 k €36,2 k €15,3 k €
Governance

Board of directors

Seen on filing of 31/12/2024 · 3 active · 6 ended

Active mandates

HP Projects

Director · 0567.695.270

Represented by Hans Peerlinck

Active
QUAESTUM

Director · 0675.654.587

Represented by Bart Claikens

Active
SCALDINO

Director · 0541.558.126

Represented by Philip Van Overschelde

Active

Ended mandates

QUAESTUM

Director · since 22 février 2022 · 0675.654.587

Represented by Bart Claikens

Ended
B-Epic

Director · since 27 octobre 2021 · 0758.931.859

Represented by Christian Bigot

Ended
HP Projects

Director · since 27 octobre 2021 · 0567.695.270

Represented by Hans Peerlinck

Ended
B-Epic

Director · 0758.931.859

Represented by Christian BIGOT

Ended
Annual accounts

Full financial information

202420232022
Type of accountMicro modelMicro modelMicro model
Start of the financial year01/01/202401/01/202327/10/2021
Closing of the financial year31/12/202431/12/202331/12/2022
Length of the financial year12 months12 months15 months
Filing date17/06/202528/08/202430/08/2023
General meeting02/06/202503/06/202405/06/2023
Currency of the financial yearEUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

3 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Micro model31/12/202402/06/202517/06/2025DutchPDF
Micro model31/12/202303/06/202428/08/2024DutchPDF
Micro model31/12/202205/06/202330/08/2023DutchPDF
Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 3 active · 6 ended

Active mandates

HP Projects

Director · 0567.695.270

Represented by Hans Peerlinck

Active
QUAESTUM

Director · 0675.654.587

Represented by Bart Claikens

Active
SCALDINO

Director · 0541.558.126

Represented by Philip Van Overschelde

Active

Ended mandates

QUAESTUM

Director · since 22 février 2022 · 0675.654.587

Represented by Bart Claikens

Ended
B-Epic

Director · since 27 octobre 2021 · 0758.931.859

Represented by Christian Bigot

Ended
HP Projects

Director · since 27 octobre 2021 · 0567.695.270

Represented by Hans Peerlinck

Ended
B-Epic

Director · 0758.931.859

Represented by Christian BIGOT

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2024
    Annual accounts 2024123,3 k €
  2. 2023
    Annual accounts 2023-65,2 k €
  3. 2022
    Annual accounts 2022-52,4 k €